Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PGT121, PGDM1400, 10-1074, and VRC07-523LS in healthy adults
NCT03928821Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2019
- Primary completion
- Mar 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of PGT121, PGDM1400LS, zinlirvimab and VRC07-523LS in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Jul 2019; status: completed.
02
Drugs
PGT121PGDM1400LSzinlirvimabVRC07-523LS
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03928821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03928821.